Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,673.59 +475.50 (+0.71%) CMC Crypto 200
1,424.48 -4.09 (-0.29%)
PCRX Jun 2024 30.000 call
| Previous close | 2.3500 |
| Open | 2.3500 |
| Bid | 1.4000 |
| Ask | 2.7500 |
| Strike | 30.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.3500 - 2.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 535 |
GlobeNewswirePacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare Conference at 11:00 AM ET on Thursday, June 6, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira BioSciences, In
Simply Wall St.Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts
Investors in Pacira BioSciences, Inc. ( NASDAQ:PCRX ) had a good week, as its shares rose 9.3% to close at US$29.86...
- GlobeNewswire
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including,
